Jazz EVP has 6,209 shares withheld for taxes
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals EVP Robert Iannone, Global Head of R&D and CMO, reported a tax-related share disposition. On March 5, 2026, 6,209 ordinary shares were withheld at a price of 188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units.
Following this tax-withholding disposition, Iannone directly holds 88,871 ordinary shares of Jazz Pharmaceuticals. This transaction reflects administrative share withholding rather than an open-market purchase or sale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Ordinary Shares | 6,209 | $188.69 | $1.17M |
Footnotes (1)
- F1. Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Jazz (JAZZ) executive Robert Iannone report?
Was Robert Iannone’s Jazz (JAZZ) Form 4 a sale in the open market?
What triggered the tax-withholding disposition reported by Jazz (JAZZ) executive Robert Iannone?
AI-generated analysis. How Rhea-AI works. Not financial advice.